Dechra Veterinary Products Partners with I-MED Pharma

Wednesday, March 17, 2021

Dechra Veterinary Products is pleased to announce its exclusive marketing, sales, and distribution agreement with I-MED Pharma, the Canadian leader in dry eye management, for three innovative veterinary hyaluronic acid (HA) ophthalmic products.

Dechra Veterinary Products is pleased to announce its exclusive marketing, sales, and distribution agreement with I-MED Pharma, the Canadian leader in dry eye management, for three innovative veterinary hyaluronic acid (HA) ophthalmic products. Dechra has licensed the North American, long-term, veterinary rights for the following three products:

• 0.20% viscoadaptive HA suspension with osmoprotectants and bioprotectants
• 0.40% viscoadaptive HA ointment
• 0.18% viscoadaptive HA solution

Dechra will be launching these new products under the brand name OphtHAvet™ and will continue to collaborate with I-MED’s Chief Scientific Officer and founder, Dr. Ilan Hofmann regarding HA research and new product development. With over 30 years of experience specializing in dry eye diagnosis and management, Dr. Hofmann is recognized as a leader in ocular surface disease and for developing the highest quality and efficacious HA ophthalmic products.

The OphtHAvet portfolio is expected to launch later this year and will be the latest addition to Dechra’s veterinary ophthalmic portfolio, which currently includes Puralube® Vet Ointment. Additionally, Dechra will be re-introducing Vetropolycin® (bacitracin-neomycin-polymyxin) veterinary ophthalmic ointment and Vetropolycin® HC (bacitracin-neomycin-polymyxin-hydrocortisone acetate 1%) veterinary ophthalmic ointment.

Philipp Binder, President of I-MED Pharma stated, “This partnership with Dechra allows us to pursue our vision of making our industry leading technology accessible to as many patients as possible. The collaboration in product development will further push the boundaries of science and ensure we can continue to bring the most cutting-edge products to market.”

Mike Eldred, President of North American Operations for Dechra, commented: “We are pleased to have partnered with I-MED Pharma and we look forward to launching these innovative HA veterinary ophthalmics. Once we regain supply of Vetropolycin and Vetropolycin HC, Dechra will be well positioned to provide veterinarians with a wide range of veterinary approved ophthalmics to help treat and resolve their everyday challenges.”

For questions or further information, please contact Mike Eldred or Doug Hubert: